eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Novartis Pharmaceuticals UK Ltd

Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR
Telephone: +44 (0)1276 692 255
Fax: +44 (0)1276 698 449
Medical Information Direct Line: +44 (0)1276 698 370
Medical Information e-mail: medinfo.uk@novartis.com
Customer Care direct line: +44 (0)845 741 9442

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Patient Information Leaflet last updated on the eMC: 12/08/2009
PIL Sandostatin Ampoules and Multidose vial

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 12/08/2009 and displayed until Current
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 25/04/2008 and displayed until 12/08/2009
Reasons for adding or updating:
  • Transfer to upgraded management system
Updated on 07/02/2008 and displayed until 25/04/2008
Reasons for adding or updating:
  • Change due to user-testing of patient information
Updated on 28/11/2007 and displayed until 07/02/2008
Reasons for adding or updating:
  • Extra statutory information
Updated on 11/04/2005 and displayed until 28/11/2007
Reasons for adding or updating:
  • Change to side-effects
Updated on 07/02/2003 and displayed until 11/04/2005
Reasons for adding or updating:
  • Update to PIL
Updated on 24/06/2002 and displayed until 07/02/2003
Reasons for adding or updating:
  • Update to PIL
Updated on 04/02/2002 and displayed until 24/06/2002
Reasons for adding or updating:
  • Update to PIL
Updated on 01/12/2000 and displayed until 04/02/2002
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   octreotide acetate